QAP (Colombia)

Microbix & Ulisse Biomed Collaborate on HPV Controls & Assays

Retrieved on: 
Friday, November 10, 2023
QAP (Colombia), BIT, OTCQX, UBM, Patient, PCR, Infection, Therapy, Human papillomavirus infection, Cancer, Business, TSX, HPV, SVP, Vaccine, Ulisse

Molecular (i.e., “PCR”) HPV Assays are used to diagnose infections and distinguish between the virus types that generate higher or lower risks of fatal cancers.

Key Points: 
  • Molecular (i.e., “PCR”) HPV Assays are used to diagnose infections and distinguish between the virus types that generate higher or lower risks of fatal cancers.
  • However, HPV Assays must be stringently monitored to ensure their accuracy – ideally with Microbix QAPs.
  • Ulisse has validated Microbix’s HPV QAPs as tools to support the ongoing accuracy of its HPV Assays and will recommend their usage in its instructions for use (“IFUs”).
  • Additionally, Microbix has created custom ONBOARDx™ kits of QAPs to assist the Ulisse sales teams in demonstrating the HPV Assays to prospective customers, as well as for training operators and for qualifying new HPV Assay installations.

Microbix QAPs Supporting HPV Testing in Ireland

Retrieved on: 
Friday, October 27, 2023
System, Cervical cancer, Thorpe Coombe Hospital, MDX, OTCQX, HPV, Business development, QAP (Colombia), Senior, Republic, MSC, Immune system, Cancer, Human papillomavirus infection, Republic of Ireland, Medical device, Roche, Woman, Marketing, TSX, Infection, Vaccine, EU

MISSISSAUGA, Ontario, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its quality assessment products (“QAPs™”) are supporting a testing program for Human Papilloma Virus (“HPV”) using molecular diagnostic (“MDx”) technology at Dublin’s The Coombe Hospital, in the Republic of Ireland, an EU member-state.

Key Points: 
  • MISSISSAUGA, Ontario, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its quality assessment products (“QAPs™”) are supporting a testing program for Human Papilloma Virus (“HPV”) using molecular diagnostic (“MDx”) technology at Dublin’s The Coombe Hospital, in the Republic of Ireland, an EU member-state.
  • Dr. Lisa Tang, Head of Sales and Marketing of MSC commented, “We are pleased to support this important women’s health initiative with Microbix’s HPV QAPs.
  • We now look forward to the roll-out of MDx-based cervical cancer screening throughout the Republic of Ireland.”
    An initial purchase order for HPV-directed QAPs has been received by Microbix and it is expected that recurring QAPs sales into Ireland will become routine.
  • Phil Casselli, Senior Vice President of Sales and Business Development of Microbix also commented, “Ireland provides an example of Microbix’s technological leadership by way of our HPV quality controls being selected to support another national HPV screening program.

Microbix Achieves New QAPs Sales Record

Retrieved on: 
Wednesday, September 27, 2023
Business development, QAP, Calendar, Infection, QuidelOrtho, QAP (Colombia), POCT, Gertrude Pocte Geddes Willis, OTCQX, TSX, Growth, SVP, Video game

are for Microbix QAPs formatted onto Copan® FLOQSwabs® to support the use of point-of-care-tests (“POCTs”) for multiple infectious diseases and disease categories.

Key Points: 
  • are for Microbix QAPs formatted onto Copan® FLOQSwabs® to support the use of point-of-care-tests (“POCTs”) for multiple infectious diseases and disease categories.
  • is nearly equivalent to a full quarter’s worth QAPs sales from 2022 and is indicative of Microbix beginning to realize its targeted sales growth for this segment.
  • is in the tens of thousands and Microbix expects ongoing sales to QuidelOrtho, with which it executed a Purchase and Supply Agreement on August 10, 2022.
  • Management believes this order substantiates diagnostics industry trends that are beneficial to Microbix and its QAPs business.

Microbix Reports Results for Q3 Fiscal 2023

Retrieved on: 
Thursday, August 10, 2023
COGS, Ageing, QAP (Colombia), ERP, OTCQX, DXTM, Antigen, TSX, YTD, Clothing, Bank, Q3

MISSISSAUGA, Ontario, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and YTD fiscal 2023 ended June 30, 2023 (“Q3” and “YTD”), a period in which strong revenues were realized along with a fully-funded partnering of its drug asset Kinlytic® urokinase (“Kinlytic”).

Key Points: 
  • MISSISSAUGA, Ontario, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and YTD fiscal 2023 ended June 30, 2023 (“Q3” and “YTD”), a period in which strong revenues were realized along with a fully-funded partnering of its drug asset Kinlytic® urokinase (“Kinlytic”).
  • For the three months ending June 30, 2023 (“Q3”)
    Q3 revenue was $5,530,152, an increase of 10% from Q3 2022 revenues of $5,011,025.
  • Such IT systems start-up costs were heaviest in Q3, as Microbix drove toward a Q4 2023 “go-live” for its new ERP system.
  • Overall, Q3 sales led to an operating and net loss of $769,108 versus a Q3 2022 operating and net income of $638,502.

Microbix Presents Results of STI Test Controls at AACC

Retrieved on: 
Monday, July 24, 2023
CT, AACC, STI, Trichomonas vaginalis, Abbott, Vertically transmitted infection, QAP (Colombia), Emerging, PCR, Point-of-care testing, Infection, Neisseria gonorrhoeae, Mycoplasma, Chlamydia trachomatis, BD, Assay, RUO, Gertrude Pocte Geddes Willis, American Association for Clinical Chemistry, NG, Mycoplasma genitalium, OTCQX, IVD, TSX, Poster, Medical imaging, Chlamydia, Trichomonas

At AACC, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.

Key Points: 
  • At AACC, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.
  • Microbix will thereby showcase its ever-growing portfolio of QAPs that help ensure the accuracy of antigen and molecular (i.e., “PCR”) tests and their workflows.
  • Microbix therefore developed a whole-workflow multiplex STI QAP desiccated on a Copan FLOQSwab® that is stable at 2-30°C and contains inactive whole-genome target pathogens.
  • We’re pleased to be offering Microbix QAPs to support clinically-important STI testing – as tools for validation, verification, and training, as external quality assessment samples, and as in-kit controls.”

50 State Report Card on Affordable Housing Policies Highlights Room for Improvement on Racial Equity, Healthy Building Practices

Retrieved on: 
Tuesday, July 18, 2023
CSH, Housing, QAP, Supportive housing, QAP (Colombia), Call-sign allocation plan, Catholic Health Initiatives, Corporation, Investment, LIHTC, City, BIPOC, Health, Property management, Construction

The report is available at: https://buildingclean.org/qap-report

Key Points: 
  • The report is available at: https://buildingclean.org/qap-report
    "QAPs serve as a valuable tool to advance progressive solutions in affordable housing," said BlueGreen Alliance Foundation State Initiatives Manager and report author Jeff Hurley.
  • I hope our findings will help improve states' QAP requirements and affordable housing standards."
  • The BlueGreen Alliance Foundation undertook this project to encourage states to create good jobs, protect health, and enhance equity in affordable housing.
  • To achieve this, the report focuses on what the pillars of QAPs should be: healthy building practices, energy efficiency, worker-friendly labor standards, and racial equity.

Microbix QAPs Supporting HPV Testing Across The Netherlands

Retrieved on: 
Wednesday, July 5, 2023
Human papillomavirus infection, BVO, Workflow, Infection, Woman, QAP (Colombia), Cervical cancer, Laboratory, Immune system, Cancer, OTCQX, HPV, MDX, TSX, BD, Vaccine, EU

The program is being driven by the instrumentation and reagents of the BD COR™ system and its Onclarity™ HPV assay.

Key Points: 
  • The program is being driven by the instrumentation and reagents of the BD COR™ system and its Onclarity™ HPV assay.
  • Microbix REDx® liquid-format IVD-regulated QAPs will be used to support the quality management system monitoring the ongoing accuracy of laboratory performance for the program.
  • Rob Schuurman, National Reference Officer for the Dutch Cervical Cancer Screening Program (BVO), noted “MDx testing for HPV improves cervical cancer screening by identifying those at-risk efficiently.
  • Close monitoring of the entire HPV testing workflow is critical to realizing this healthcare goal and Microbix’s HPV QAPs have been selected to support the quality assessment monitoring of the molecular testing process, a vital part of BVO’s quality management system.”

Microbix & Labquality Create Novel Testing Accreditation Program

Retrieved on: 
Tuesday, June 20, 2023
GUD, HSV, Treponema, Accreditation, Mouth ulcer, EQA, Infection, Mpox, QAP (Colombia), Treponema pallidum, Project management, Varicella zoster virus, OTCQX, TSX, Diagnosis, Disease, Pharmaceutical industry

MISSISSAUGA, Canada and HELSINKI, Finland, June 20, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter and Labquality Oy (Labquality), a global provider of laboratory external quality assessment (“EQA”) programs, announce their creation of the world’s first program to support accreditation of clinical laboratories for detecting the pathogens most commonly causing genital ulcer disease (“GUD”).

Key Points: 
  • This novel Labquality EQA program will help ensure the proficiency of clinical labs testing to diagnose the pathogens that cause GUD.
  • In turn, Labquality has designed and is managing this GUD-oriented EQA program – which is now offered to labs in 60 countries.
  • Juha Wahlstedt, Sales Director at Labquality, commented, “We’re pleased to be employing Microbix’s innovative QAPs for this new and important EQA program.
  • Our expertise was joined to that of Labquality and Copan to ensure accurate testing and properly-directed treatment is widely available for GUD patients.”

Microbix Supporting Australian Point-of-Care Testing Program

Retrieved on: 
Wednesday, March 1, 2023
TSX, Test management, Gertrude Pocte Geddes Willis, Diagnosis, Neisseria gonorrhoeae, OTCQX, Chlamydia trachomatis, QAP (Colombia), Business development, STI, Trichomonas vaginalis, MDX, SVP, Health, Point-of-care testing, Medical device, Trichomonas, Chlamydia

MISSISSAUGA, Ontario, March 01, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its Quality Assessment Products (“QAPs™”) are now supporting test accuracy within a program to provide Point-of-Care Testing (“PoCT”) for Sexually-Transmitted Infections (“STIs”) in remote communities across Australia.

Key Points: 
  • MISSISSAUGA, Ontario, March 01, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its Quality Assessment Products (“QAPs™”) are now supporting test accuracy within a program to provide Point-of-Care Testing (“PoCT”) for Sexually-Transmitted Infections (“STIs”) in remote communities across Australia.
  • It is therefore honoured to be supporting this Australian program for STI testing in remote communities, which Microbix believes is providing a worldwide model for helping underserved populations.
  • Philip Hill, General Manager of r-Biopharm Australia commented, “r-Biopharm is pleased that the program will be delivering world-class diagnostic testing to some of the most remote populations in Australia.
  • This program, supported by PROCEEDxFLOQ QAPs, should help to provide the kind of testing needed in these Australian communities.”
    Microbix’s FLOQSwab-based QAPs support both STIs and other disease categories, with the full catalogue available at https://microbix.com and purchase enquiries directed to [email protected] .

Microbix Presenting Results of Collaboration with Health PEI

Retrieved on: 
Monday, February 6, 2023
PEI, BD (company), Infection, RUO, Becton, Dickinson and Company headquarters, Pathology, BD, Queen Elizabeth Hospital, Cancer, IVD, Diagnosis, TSX, European, Risk, Poster, QAP (Colombia), Cervical cancer, OTCQX, Sale, Health PEI, MDX, National Microbiology Laboratory, Microbiology, HPV, Death, Vaccine, Neoplasm

Microbix’s Quality Assessment Products (“QAPs™”) supporting test and test-workflow accuracy enabled it to assist Health PEI in verifying functionality and implementing use of the Becton Dickinson (“BD”) Onclarity™ HPV assay.

Key Points: 
  • Microbix’s Quality Assessment Products (“QAPs™”) supporting test and test-workflow accuracy enabled it to assist Health PEI in verifying functionality and implementing use of the Becton Dickinson (“BD”) Onclarity™ HPV assay.
  • Microbix HPV QAPs are available for sale in Canada, Australia, Europe, the United States, and other jurisdictions under its “REDx™ Controls” (IVD) or “PROCEEDx™” (RUO) brand names.
  • Diagnostic tests to detect infection with high-risk HPV provide important preventative health information and require validated, regulated, and third-party test-controls to help ensure their accuracy.
  • Microbix believes high-risk HPV infections and resulting cancers have gone undiagnosed and is pleased to help enable new MDx screening programs.